Jul 06, 2013, 02.50 PM | Source: CNBC-TV18
Gautam Sinha Roy of Motilal Oswal Securities expects 7-8 percent upside in Lupin in near term.
Gautam Sinha Roy (more)
VP-Equity Strategy & Product, | Capital Expertise: Equity - Fundamental
"So, lot of positive tailwinds are there for Lupin. That is the main reason why we continue to like this stock at this point of time," he added.
However, SP Tulsian, CEO at sptulsian.com finds it
"US subsidiary, Lupin Pharmaceuticals Inc has laun
"We are confident that this partnership for Loftai
Lupin Pharmaceuticals launched GAVIS Pharmaceutica
On CNBC-TV18's show Super Six, market gurus Vishal
Union Bank of India | ONGC | BHEL | Akzo Noble | F